Inotek Pharmaceuticals, a biotech developing a small molecule eye drop therapy to treat glaucoma, announced terms for its IPO on Thursday. The Lexington, MA-based company plans to raise $65 million by offering 4.6 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Inotek Pharmaceuticals would command a fully diluted market value of $200 million.
Inotek Pharmaceuticals, which was founded in 1999, plans to list on the NASDAQ under the symbol ITEK. Cowen & Company, Piper Jaffray, Canaccord Genuity and Nomura Securities are the joint bookrunners on the deal. It is expected to price during the week of February 2, 2015.
Keep an eye on it: Inotek Pharmaceuticals sets terms for $65 million IPO
January 22, 2015

